UK OTC Industry Welcomes Post-Brexit Drug Import Batch Testing Solution
UK consumer healthcare industry association, PAGB welcomes the UK government's recent announcement that its policy of not requiring domestic batch testing or certification of medicines imported from the EU/European Economic Area is to be made permanent.
You may also be interested in...
One of the key regulatory conundrums thrown up by Brexit has been addressed after the government decided to continue using a list of approved countries to waive drug import testing requirements.
Recognition of EU/EEA batch testing of imported medicines by UK will not be ending on 1 January 2023, and companies will be given two years notice if anything changes, says MHRA.
German consumers are “generally willing to accept price increases from OTC manufacturers” when it comes to core categories like cough, cold & flu, finds Sempora, and are increasingly willing to shell out for trending gut health products like probiotics.